Johnson & Johnson (NYSE:JNJ) Shares Up 1.9% – Should You Buy?

Johnson & Johnson (NYSE:JNJ) was up 1.9% during mid-day trading on Tuesday . The stock traded as high as $214.39 and last traded at $213.7790. Approximately 10,819,306 shares traded hands during mid-day trading, an increase of 30% from the average daily volume of 8,347,143 shares. The stock had previously closed at $209.72.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Delaware’s top court tossed part of a $1 billion damages award tied to J&J’s abandoned Auris Health deal and ordered a recalculation of damages, which materially reduces potential liability uncertainty. Court Orders Recalculation Of Damages In Johnson & Johnson Auris Case
• Positive Sentiment: J&J reported strong long-term Rybrevant results in metastatic colorectal cancer (RAS/BRAF wild-type) presented at ASCO — a clinical win that can boost oncology revenue potential and support valuation of the cancer franchise. Johnson & Johnson Therapy Delivers Strong Results In Colorectal Cancer Trial
• Positive Sentiment: New Phase 3 analyses for CAPLYTA and other depression treatments will be presented at ACNP, underscoring ongoing psychiatric pipeline progress that could support future specialty sales. Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
• Positive Sentiment: Quarterly commentary and investor letters highlight drivers that lifted JNJ in Q4 (diversified pharma and MedTech momentum), reinforcing the narrative of steady underlying performance. Here’s What Lifted Johnson & Johnson (JNJ) in Q4
• Neutral Sentiment: J&J presented at the J.P. Morgan Healthcare Conference; the transcript provides management’s strategic outlook and may influence short-term investor positioning but contains no single market-moving surprise. Johnson and Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Analysts note MedTech momentum driven by cardiovascular strength and new product rollouts — a supportive growth narrative ahead of Q4 results, though the update is forward-looking rather than immediate earnings news. What’s Powering J&J’s MedTech Growth Ahead of Q4 Release?
• Negative Sentiment: Outlook risk: the same MedTech coverage also flags lingering pressure in China that could weigh on near-term MedTech sales growth and margins in upcoming quarters. What’s Powering J&J’s MedTech Growth Ahead of Q4 Release?

Analyst Ratings Changes

JNJ has been the topic of a number of recent research reports. Stifel Nicolaus raised their price objective on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a research note on Wednesday, October 15th. Citigroup upped their target price on shares of Johnson & Johnson from $215.00 to $232.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Wolfe Research lifted their price target on Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a research note on Monday, January 5th. Cowen reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Four equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $213.33.

Johnson & Johnson Stock Up 1.9%

The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $515.06 billion, a P/E ratio of 20.64, a P/E/G ratio of 2.10 and a beta of 0.34. The stock’s 50-day simple moving average is $203.34 and its 200-day simple moving average is $185.38.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. As a group, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Institutional Investors Weigh In On Johnson & Johnson

A number of hedge funds have recently made changes to their positions in JNJ. Abich Financial Wealth Management LLC purchased a new stake in Johnson & Johnson during the third quarter worth about $26,000. Evolution Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $27,000. Clayton Financial Group LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter worth approximately $28,000. Semmax Financial Advisors Inc. raised its holdings in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after purchasing an additional 72 shares during the period. Finally, GFG Capital LLC bought a new position in Johnson & Johnson during the second quarter valued at $35,000. 69.55% of the stock is currently owned by institutional investors.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.